Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production.

α-Neoendorphin

GRP-60367 is the first small molecule rabies virus (RABV) entry inhibitor, which has nanomolar effect on some RABV strains.Grp-60367 inhibits the entry of a subset of the RABV strain.Grp-60367 showed the specificity and effective anti-RABV activity of the scaffold. In the dose-response analysis, the EC50s range from 2 to 52 nM in different host cell lines.